STOCK TITAN

STERIS plc (STE) SEC Filings, Nov 2025-Mar 2026

STE NYSE

STERIS plc filings document material events for an Ireland-incorporated operating company with ordinary shares traded as STE on the New York Stock Exchange. Recent Form 8-K reports cover results of operations and financial condition, attached earnings releases, director appointments and retirements, officer transition arrangements, and compensation-related amendments.

The filing record also identifies STERIS securities registered under Section 12(b), including ordinary shares and NYSE-listed senior notes due 2031 and 2051. These disclosures frame the company’s capital structure, governance actions, executive-compensation matters, and periodic operating-result announcements for its infection-prevention and life sciences business.

Form 144
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.35%
Tags
other
-
Rhea-AI Summary

STERIS plc reported solid growth for the nine months ended December 31, 2025. Total revenues rose to $4,347.5 million from $3,979.0 million, with balanced increases in Healthcare, AST, and Life Sciences. Net income attributable to shareholders grew to $562.1 million, and diluted EPS from continuing operations increased to $5.69 from $4.68.

Gross profit reached $1,929.4 million, while operating income from continuing operations improved to $785.0 million, despite $5.1 million of acquisition and integration expenses and $3.0 million of restructuring costs. Cash flow from operating activities was strong at $1,006.0 million, supporting capital expenditures of $278.8 million and share repurchases of $161.2 million plus $180.0 million in dividends.

The balance sheet showed cash and cash equivalents of $423.7 million and total debt of $1,898.4 million, with shareholders’ equity rising to $7,154.5 million. The company completed the Dental segment sale (reported as discontinued operations) and continues to manage restructuring in its Healthcare surgical business in Europe and an ethylene oxide litigation settlement framework in Illinois, as well as ongoing IRS tax matters.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.68%
Tags
quarterly report
-
Rhea-AI Summary

STERIS plc filed a current report stating that it has released financial results for its fiscal 2026 third quarter, covering the quarter ended December 31, 2025. The company announced these results through a press release dated February 4, 2026, which is attached as Exhibit 99.1 and furnished, rather than filed, with regulators.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.74%
Tags
current report
Rhea-AI Summary

STERIS plc filed a Form 4 reporting an equity award to a company officer. On January 2, 2026, a STERIS officer serving as VP, Chief Comp. & Quality Officer acquired 798 ordinary shares of STERIS plc at a reported price of $0 per share, indicating a share grant rather than an open-market purchase.

After this transaction, the officer beneficially owned 5,028 ordinary shares directly, of which 3,750 shares were restricted as of January 2, 2026. These restricted shares are scheduled to vest in tranches between May 31, 2026 and January 2, 2029. In addition, units representing 248 ordinary share equivalents were held for the officer under the STERIS Corporation 401(k) Plan as of that same date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
insider
-
Rhea-AI Summary

STERIS plc executive John P. Ubbing, Vice President, Chief Compliance & Quality Officer, reports his beneficial ownership in the company as of early 2026. He directly holds 4,230 ordinary shares, of which 2,952 are restricted. These restrictions are scheduled to lapse in stages: 660 shares on May 31, 2026; 1,128 shares on June 2, 2026; 588 shares on June 4, 2027; and 576 shares on June 3, 2028.

In addition, Ubbing has an indirect interest in 248 ordinary share equivalents held for him under the STERIS Corporation 401(k) Plan. He also holds several employee stock options: 2,480 options at an exercise price of $219.97 expiring May 31, 2033; 2,008 options at $251.34 expiring June 4, 2034; and 2,056 options at $267.66 expiring June 3, 2035, each with multi-year vesting schedules that gradually become exercisable.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
insider
-
Rhea-AI Summary

STERIS plc (STE) reported insider transactions by its Sr. VP and GM, Life Sciences, on November 21, 2025. The officer exercised employee stock options to buy 2,872 ordinary shares at $114.22 and 2,136 ordinary shares at $147.05, then sold the same numbers of shares in two sales at $262 per share. Following these transactions, the officer beneficially owned 10,710 ordinary shares.

As of November 21, 2025, 4,003 of these 10,710 ordinary shares are restricted, with restrictions scheduled to lapse in several tranches between June 1, 2026 and June 5, 2028. The reported stock options are described as fully vested and now show 0 derivative securities remaining after the exercises.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
insider
Rhea-AI Summary

STERIS plc (STE) insider filed a Form 144 to sell 5,008 ordinary shares. The planned sale is through Charles Schwab & Co., Inc. on the NYSE, with an approximate sale date of 11/21/2025. The shares listed have an aggregate market value of $1,312,096.00, and the table notes 98,147,009 shares outstanding. The seller acquired these shares on 11/21/2025 through an employee stock option exercise, using a broker payment for a cashless exercise.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
other
-
Rhea-AI Summary

STERIS plc (STE) officer and V.P. & Corporate Treasurer reported option exercises and share sales. On November 18, 2025, the insider exercised an employee stock option for 3,536 ordinary shares at an exercise price of $182.22 per share, then sold shares in several transactions at market prices around the mid-$250s. Reported sales included 3,324 shares at a weighted average price of $257.43, 212 shares at a weighted average price of $258.03, and 1,500 shares at $257.76 per share.

After these transactions, the reporting person beneficially owned 5,695 ordinary shares, including 1,475 restricted shares as of November 18, 2025. The restricted shares are scheduled to vest in installments between June 1, 2026 and June 5, 2028, and the reported stock option is now fully vested with no remaining balance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
insider
-
Form 144
Rhea-AI Summary

STERIS plc (STE) insider activity is disclosed in a Form 144 notice indicating an intention to sell 5,036 ordinary shares. The planned sale, through Charles Schwab & Co., Inc., has an aggregate market value of $1,297,033 and is expected to occur around 11/18/2025 on the NYSE. The company reports 98,147,009 shares outstanding, so this planned sale represents a small portion of total shares.

The securities to be sold were acquired mainly through equity compensation from STERIS plc, including an employee stock option exercise of 3,536 shares on 11/18/2025 via a broker-assisted cashless exercise and several restricted stock lapses between 05/31/2023 and 10/01/2024. The notice also reports that the same holder sold 3,204 shares of STERIS on 08/20/2025 for gross proceeds of $798,560 in the past three months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
other
Rhea-AI Summary

STERIS plc (STE) Form 4: The company’s Senior Vice President, General Counsel and Secretary exercised 15,000 employee stock options at $69.72 per share on 11/11/2025 and sold 15,000 ordinary shares the same day at a weighted average price of $265.14 (range $265.00–$265.95). Following these transactions, the officer directly owned 33,669 shares as of 11/11/2025. Of these, 8,511 are restricted, with scheduled lapses through June 2028.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
insider

FAQ

How many STERIS plc (STE) SEC filings are available on StockTitan?

StockTitan tracks 123 SEC filings for STERIS plc (STE), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for STERIS plc (STE)?

The most recent SEC filing for STERIS plc (STE) was filed on November 13, 2026.